Drug Type Trispecific T-cell engager (TriTE) |
Synonyms ZG 006, ZG-006, ZG006 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), DLL3 inhibitors(Delta-like protein 3 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Breakthrough Therapy (China) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Recurrent Lung Small Cell Carcinoma | Phase 3 | China | 23 Sep 2025 | |
| Neuroendocrine Carcinoma | Phase 2 | - | 01 Aug 2025 | |
| Prostate Neuroendocrine Carcinoma | Phase 2 | China | 10 Jun 2025 | |
| Large cell neuroendocrine carcinoma of lung | Phase 2 | China | 13 Aug 2024 | |
| Advanced Neuroendocrine Carcinoma | Phase 2 | China | 12 Aug 2024 | |
| Advanced Lung Small Cell Carcinoma | Phase 2 | China | 19 Oct 2023 | |
| Extensive stage Small Cell Lung Cancer | Phase 1 | China | 05 Nov 2025 | |
| Small Cell Lung Cancer | Phase 1 | United States | 31 Mar 2025 |
Phase 2 | 17 | lwewuuznff(ssgwgoscqx) = tixeyjopph ozztenakmy (tmixrfgufj ) View more | Positive | 30 May 2025 | |||
Phase 1 | 45 | wvcqrgqhxf(imwzkiyieq) = eejjpkjyci qhhcdarlzy (ymumsqexud ) View more | Positive | 30 May 2025 | |||
Phase 2 | 40 | dtfhgzuauh(cpegwfoapg) = pgycwqirrn ommfqzswsy (fhuczrgkad ) View more | Positive | 30 May 2025 | |||
dtfhgzuauh(cpegwfoapg) = xmcewxcahq ommfqzswsy (fhuczrgkad ) View more | |||||||
Phase 1/2 | 24 | vupptydfen(lbbcbagfsm) = 绝大多数治疗相关不良事件(TRAEs)的严重程度为1级或2级。最常见的TRAEs为发热、贫血和细胞因子释放综合征(CRS,3级CRS 1例)。 fciztwszal (yrrwxzxlhd ) View more | Positive | 25 Sep 2024 |






